Wu YL, Zhang L, Fan Y, Zhou J, et al. Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score >/=1%: KEYNOTE-042 China study. Int J Cancer 2025 Dec 31. doi: 10.1002/ijc.70265.
PMID: 41474069